OS Therapies(OSTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OSTX OS Therapies

Market Closed 03-28 16:00:00 EDT

1.62

+0.00

0.00%

盘后1.62

+0.000.00%

18:09 EDT

High1.65	Low1.54	Vol66.28K
Open1.60	D1 Closing1.62	Amplitude6.79%
Mkt Cap35.52M	Tradable Cap24.35M	Total Shares21.93M
T/O105.06K	T/O Rate0.44%	Tradable Shares15.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.62,"timestamp":1743192000000,"preClose":1.62,"halted":0,"volume":66278,"hourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.62,"latestTime":"18:09 EDT","volume":321,"amount":518.6931,"timestamp":1743199750020},"delay":0,"floatShares":15030400,"shares":21928300,"eps":-0.763024,"marketStatus":"Market Closed","change":0,"latestTime":"03-28 16:00:00 EDT","open":1.6,"high":1.65,"low":1.54,"amount":105057.7350016,"amplitude":0.067901,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.763024,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.62,"postHourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.62,"latestTime":"18:09 EDT","volume":321,"amount":518.6931,"timestamp":1743199750020},"volumeRatio":0.749785},"requestUrl":"/m/hq/s/OSTX/wiki","defaultTab":"wiki","newsList":[{"id":"2521055402","title":"OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521055402","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521055402?lang=en_us&edition=full_marsco","pubTime":"2025-03-23 20:49","pubTimestamp":1742734185,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where OS Therapies Incorporated  stands against other penny stocks with the biggest upside potential.Further insights came from Chris Retzler, portfolio manager for Needham’s Small Cap Growth Fund, who shared his outlook for small-caps on CNBC’sSquawk Boxon January 17, 2025. He noted that small-cap companies are looking for policy certainty, and once the new administration’s direction becomes clearer, we could see growth accelerate. Globally, the EV sector is thriving, even as it faces some hurdles in the United State","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-ostx-among-penny-124945078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2521400452","title":"OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400452","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400452?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:40","pubTimestamp":1742557200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 21, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong, CBO will be accepting meetings with registered investors at The Jones Healthcare and Technology Innovation Conference. The conference is being held on April 8-9, 2025 at the Venetian Resort in Las Vegas. The Company’s participation aligns with its prioritization of advancements in healthcare and technology while connecting with other investors.Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as \"anticipate,\" \"expect,\" \"intend,\" \"may,\" \"will,\" \"should\" or other comparable terms involve risks and uncertainties because they rela","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-attend-jones-healthcare-114000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","OSTX","BK4080","BK4139","BK4137","BK4231","HCSG","OS","BK4097"],"gpt_icon":0},{"id":"2519838093","title":"OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519838093","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519838093?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:40","pubTimestamp":1741866000,"startTime":"0","endTime":"0","summary":"NEW YORK, March 13, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company’s Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma. This data will be compared with a newly created regulatorily compliant synthetic control group comprised of case matched controls that will be used for the Company’s US Food & Drug Administration  OST-HER2 Biologics License Application  submission. Equivalent submissions with international regulatory authorities will be made in order to gain commercial marketing authorization. MIB Agents FACTOR is the most important annual osteosarcoma conference bringing together the leading osteosarcoma researchers, clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-awarded-ost-her2-114000281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4017","BK4139","OST","BK4231","OS","ADC","DC","BK4148","BK4097","OSTX"],"gpt_icon":0},{"id":"2518748676","title":"OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748676?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:51","pubTimestamp":1741693876,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative Licensing an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-schedules-scientific-advice-meeting-for-ost-her2-in-q3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-schedules-scientific-advice-meeting-for-ost-her2-in-q3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OST","OSTX","BK4148","BK4139"],"gpt_icon":0},{"id":"2518418748","title":"OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2518418748","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518418748?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:40","pubTimestamp":1741693200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 11, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting  in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway  with the United Kingdom’s  Medicines and Healthcare products Regulatory Agency  for OST-HER2, its immunotherapy candidate for the prevention of recurrence of metastases in osteosarcoma. The Company released positive Phase 2b data in January 2025 that demonstrates statistically significant results in the primary endpoint of the study, 12-month event free survival . The meeting with MHRA has been scheduled to position the Company to bring OST-HER2 to market in the UK in 2025.\"Today’s announcement marks the beginning of the regulatory process required to bring our OST-HER2 immunotherapy to market globally,\" stated OS Therapies’ CEO Paul Romness. \"As we prepare for regulatory in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-schedules-united-kingdom-114000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCO","UBCP","BK4528","BK4532","BK4211","UK","SAM","ADC","BK4233","HCSG","BK4231","BK4148","OST","BK4205","BK4017","BK4080","OS","BK4139","BK4137","BK4588","OSTX","DC","BK4585","BK4158","BK4097"],"gpt_icon":0},{"id":"2514189327","title":"Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2514189327","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514189327?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc.  and OS Therapies Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-os-therapies-interviews-140000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4187","AIRI","ET","BK4561","ADC","BK4099","BK4604","CLDI","TV","BK4097","03160","BK4590","BK4139","BK4555","OSTX","BK4588","BK4585","BK4100","BK4231","OS","BK4581","BK4144","BK4080","TM"],"gpt_icon":0},{"id":"2514186726","title":"Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186726","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514186726?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"NEW YORK, February 26, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar on February 27, 2025, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature OS Therapies’ Chairman and CEO, Paul Romness, and Chief Business Officer, Gerald Commissiong, who will provide an in-depth update on the Company’s rapidly advancing pipeline. OS Therapies is pioneering groundbreaking immunotherapies and antibody-drug conjugates  to address critical unmet needs in pediatric and young adult oncology, as well as a broad range of solid tumors. The Company’s lead candidate, OST-HER2, has demonstrated statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning it as a potential first-in-class treatment with accelerated FDA approval pathways. Additionally, OS Therapies’ proprietary Tunable Antibody Drug Conjug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-os-therapies-exclusive-live-210100765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4139","OSTX","BK4231","OS","BK4080","ADC"],"gpt_icon":0},{"id":"2513072902","title":"OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2513072902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513072902?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:43","pubTimestamp":1740404601,"startTime":"0","endTime":"0","summary":"OS Therapies  said Monday it has formed OS Drug Conjugates unit and initiated a review of strategic options for its tunable antibody-drug conjugates and other tunable drug conjugates platforms.The biotechnology company said it has started talks with antibody-drug conjugates therapeutics companies in the US, China, and other jurisdictions for potential joint ventures that will be spun off into standalone public companies.Shares of the company rose more than 8% in recent Monday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4139","BK4231","ADC","OSTX"],"gpt_icon":0},{"id":"2513872504","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513872504","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513872504?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 08:00 ET (13:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2513723879","title":"Os Therapies Forms Subsidiary Os Drug Conjugates and Initiates Review of Strategic Options for Its Tunable ADC & Drug Conjugates Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2513723879","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513723879?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 20:25","pubTimestamp":1740399900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUAB5BPPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2513233127","title":"Os Therapies Inc - in Discussions to Form Joint Ventures With ADC Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2513233127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513233127?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 20:25","pubTimestamp":1740399900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUAB5BPPP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2512412906","title":"OS Therapies receives patent notice of allowance for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2512412906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512412906?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 18:20","pubTimestamp":1740046834,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) announced that it received a notice of allowance from the United States Patent & Trademark Office that a patent will be issued ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-receives-patent-notice-of-allowance-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-receives-patent-notice-of-allowance-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OSTX","OST","BK4148"],"gpt_icon":0},{"id":"2511612270","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2511612270","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511612270?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 04:57","pubTimestamp":1739566675,"startTime":"0","endTime":"0","summary":"Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each shedding about 0.9%.The iShares Biotechnology ETF  eased 0.2%.In corporate news, enGene  shares fell past 7% after UBS downgraded the stock to neutral from buy and cut its price target to $7 from $34.Moderna  reported a Q4 loss of $2.91 per share, worse than the $2.83 loss expected in a FactSet poll. Revenue was $966 million, better than the consensus estimate of $942.8 million. Its shares gained about 4%.OS Therapies  shares jumped 12%. The firm said it signed agreements for the commercial-ready manufacturing of OST-HER2 to support anticipated Biologics Licensing Authorization filing.West Pharmaceutical Services  shares popped past 7%.  Deutsche upgraded the stock to buy from hold while lowering its price target to $250 from $275.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4568","BK4585","WST","BK4567","BK4121","IE00B64QTZ34.USD","NPCE","BK4501","OSTX","BK4504","BK4139","BK4532","BK4548","BK4588","XLV","BK4533","BK4539","MRNA","BK4082","BK4551","BK4581","IBB","BK4534","ENGN"],"gpt_icon":1},{"id":"2511645023","title":"Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2511645023","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511645023?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 02:51","pubTimestamp":1739559089,"startTime":"0","endTime":"0","summary":"On Friday, OS Therapies, Inc.  entered into agreements for the commercial manufacture of OST-HER2.The company is currently organizing additional data about the recently completed treatment phase of its Phase 2b trial of OST-HER2 to prevent recurrence of lung metastatic osteosarcoma in preparation for a Type B or Type C FDA.Following the FDA meeting, the company anticipates submitting a Biologics Licensing Authorization  application to the FDA for accelerated or conditional approval consideration.In January, OS Therapiesrevealed data from a Phase 2b trial of OST-HER2 , a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.Further, as of the most recent follow-up, the data show a strong trend in favor of OST-HER2-treated patients in overall survival  at the 1-year and 2-year interim time points of the ongoing 3-year overa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-cap-os-therapies-inks-185129548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IP","BK4136","LU2463526074.USD","BK4585","OSTX","BK4139","BK4588"],"gpt_icon":0},{"id":"2511991096","title":"BUZZ-OS Therapies rises after starting commercial production of cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511991096","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511991096?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 22:57","pubTimestamp":1739545028,"startTime":"0","endTime":"0","summary":"BUZZ-OS Therapies rises after starting commercial production of cancer therapy  ** Shares of drug developer OS Therapies OSTX.A rise 31.1% to $2.61 in morning trade  ** Co says it is starting commerci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nL4N3P516S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2511225695","title":"OS Therapies Says It Signed Manufacturing Deal for Lead Candidate OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2511225695","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511225695?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 22:29","pubTimestamp":1739543355,"startTime":"0","endTime":"0","summary":"OS Therapies  said Friday it has signed agreements to begin commercial manufacturing of its lead asset OST-HER2 as it prepares for a potential Biologics License Application submission to the US Food and Drug Administration.The company said it is compiling additional data from its recently completed phase 2b trial of OST-HER2 for lung metastatic osteosarcoma recurrence prevention.It plans to meet with the FDA for regulatory discussions before submitting a BLA for accelerated or conditional approval, OS Therapies added.Shares of the company were up more than 36% in recent Friday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4148","BK4139","OST","OSTX"],"gpt_icon":0},{"id":"2511249667","title":"BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511249667","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511249667?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 21:03","pubTimestamp":1739538228,"startTime":"0","endTime":"0","summary":"BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) FilingFeb 14 (Reuters) - OS Therapies Inc OSTX.A:OS THERAPIES INI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2511621506","title":"Os Therapies Initiates Commercial-Ready Manufacturing of Ost-Her2 to Support Anticipated Biologics Licensing Authorization (Bla) Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511621506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511621506?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 20:36","pubTimestamp":1739536584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2508453448","title":"Os Therapies: Evaluating Strategic Options for Tunable Antibody Drug Conjugate Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2508453448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508453448?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 20:33","pubTimestamp":1738672380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA1FFWSZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2508145344","title":"Os Therapies Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2508145344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508145344?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 20:33","pubTimestamp":1738672380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA1FFWSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ostherapies.com","stockEarnings":[{"period":"1week","weight":0.0189},{"period":"1month","weight":-0.0241},{"period":"3month","weight":-0.686},{"period":"6month","weight":-0.4375},{"period":"1year","weight":-0.595},{"period":"ytd","weight":-0.6215}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"AMEX","name":"OS Therapies","nameEN":"OS Therapies"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OS Therapies(OSTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OS Therapies(OSTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OS Therapies,OSTX,OS Therapies股票,OS Therapies股票老虎,OS Therapies股票老虎国际,OS Therapies行情,OS Therapies股票行情,OS Therapies股价,OS Therapies股市,OS Therapies股票价格,OS Therapies股票交易,OS Therapies股票购买,OS Therapies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OS Therapies(OSTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OS Therapies(OSTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction